Real-World Outcomes of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Era of Novel Therapies: A Canadian Perspective

Veilleux, Olivier; Claveau, Jean-Sébastien; Alaoui, Habiba; Roy, Jean; Ahmad, Imran; Delisle, Jean-Sébastien; Kiss, Thomas; Bambace, Nadia M.; Bernard, Léa; Cohen, Sandra; Sauvageau, Guy; Fleury, Isabelle; Mollica, Luigina; Roy, Denis‐Claude; Seroukh, Yasmina; Lachance, Silvana

doi:10.1016/j.jtct.2021.12.005

Cited by 4 publications

(6 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CR rate is between 17 and 75% with traditional salvage treatments (DHAP, ESHAP, IGEV, ICE) [ 21 ], but the potential for achieving CR has expanded with the advent of targeted therapies (BV, PD1 inhibitors). Single-agent BV as a salvage therapy has a 34% CR rate and 75% overall response rate (ORR) in heavily pretreated patients [ 22 ], while different BV-based combined therapies (BV-Bendamustin, BV-DHAP, BV-ESHAP, BV-gemcitabine, BV-ICE) presented far superior remission rates (CR 69–81%, ORR 74–95%) [ 23 ]. The outcome of AHSCT, chances of recovery, and survival of those patients who relapse after transplantation are also improved by incorporating these treatment options into HL therapy.…”

Section: Discussionmentioning

confidence: 99%

“…A few clinical studies have confirmed the improved survival after AHSCT, but there was a difference between studies based on the use of BV [ 23 – 29 ].…”

Section: Discussionmentioning

confidence: 99%

“…As a result of this process, the proportion of HL patients receiving BV therapy before AHSCT is growing by the day. Veilleux et al analyzed the data of 89 R/R HL patients who underwent AHSCT between 2007 and 2019 [ 23 ]. The median follow-up was 5 years, and the estimated 5-year PFS and OS were 57.5% and 81.3%, respectively.…”

Section: Discussionmentioning

confidence: 99%

“…Only 9 patients were receiving BV treatment before AHSCT. The cumulative incidence of relapse was 34%, with 18 patients deceased [ 23 ]. Akay et al investigated 75 patients who underwent AHSCT between 2016 and 2019 [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Improved survival of autologous stem cell transplantation in primary refractory and relapsed Hodgkin lymphoma in the brentuximab vedotin era — real-world data from Hungary

Husi

Pinczés

et al. 2023

Ann Hematol

View full text Add to dashboard Cite

Autologous stem cell transplantation (ASCT) is the standard treatment of primary refractory or relapsed Hodgkin-lymphoma, which can provide a cure rate of about 50%. The aim of our study was to analyze the data of 126 HL patients undergoing AHSCT in Hungary between 01/01/2016 and 31/12/2020. We assessed the progression-free and overall survival, the prognostic role of PET/CT performed before transplantation and effect of brentuximab vedotin (BV) treatment on survival outcomes. The median follow-up time from AHSCT was 39 (1–76) months. The 5-year OS comparing PET- and PET + patients was 90% v. 74% (p = 0.039), and 5-year PFS was 74% v. 40% (p = 0.001). There was no difference in either OS or PFS compared to those who did not receive BV before AHSCT. We compared BV treatments based on their indication (BV only after AHSCT as maintenance therapy, BV before and after AHSCT as maintenance treatment, BV only before AHSCT, no BV treatment). There was statistically significant difference in the 5-year PFS based on the inication of BV therapy. Recovery rates of our R/R HL patient population, who underwent AHSCT, improved significantly. Our positive results can be attributed to the PET/CT directed, response-adapted treatment approach, and the widespread use of BV.

show abstract

Section: Discussionmentioning

confidence: 99%

“…A few clinical studies have confirmed the improved survival after AHSCT, but there was a difference between studies based on the use of BV [ 23 – 29 ].…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Improved survival of autologous stem cell transplantation in primary refractory and relapsed Hodgkin lymphoma in the brentuximab vedotin era — real-world data from Hungary

Husi

Pinczés

et al. 2023

Ann Hematol

View full text Add to dashboard Cite

show abstract

“…In addition, autologous and allogeneic hematopoietic cell transplantation have been occupying a relevant place in treating R/R HL since several decades. Last but not the least, other investigational cellular therapies have raised increased interest as potentially efficacious anti-CD30 targeting model [ 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma

Leroyer

Ziegler

Moulin

et al. 2022

JCM

View full text Add to dashboard Cite

Despite years of clinical progress which made Hodgkin lymphoma (HL) one of the most curable malignancies with conventional chemotherapy, refractoriness and recurrence may still affect up to 20–30% of patients. The revolution brought by the advent of immunotherapy in all kinds of neoplastic disorders is more than evident in this disease because anti-CD30 antibodies and checkpoint inhibitors have been able to rescue patients previously remaining without therapeutic options. Autologous hematopoietic cell transplantation still represents a significant step in the treatment algorithm for chemosensitive HL; however, the possibility to induce complete responses after allogeneic transplant procedures in patients receiving reduced-intensity conditioning regimens informs on its sensitivity to immunological control. Furthermore, the investigational application of adoptive T cell transfer therapies paves the way for future indications in this setting. Here, we seek to provide a fresh and up-to-date overview of the new immunotherapeutic agents dominating the scene of relapsed/refractory HL. In this optic, we will also review all the potential molecular mechanisms of tumor resistance, theoretically responsible for treatment failures, and we will discuss the place of allogeneic stem cell transplantation in the era of novel therapies.

show abstract

Stem cell Transplant in Hodgkin Lymphoma: An Evolving Field

Durani

2022

Transplantation and Cellular Therapy

View full text Add to dashboard Cite

Real-World Outcomes of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Era of Novel Therapies: A Canadian Perspective

Cited by 4 publications

References 49 publications

Improved survival of autologous stem cell transplantation in primary refractory and relapsed Hodgkin lymphoma in the brentuximab vedotin era — real-world data from Hungary

Improved survival of autologous stem cell transplantation in primary refractory and relapsed Hodgkin lymphoma in the brentuximab vedotin era — real-world data from Hungary

Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma

Stem cell Transplant in Hodgkin Lymphoma: An Evolving Field

Contact Info

Product

Resources

About